Combination pembrolizumab and reduced-dose ipilimumab: how low can you go?
The risks of combining therapies in renal cell carcinoma and bladder cancer
Treating non-clear cell renal cell carcinoma patients
Renal cell carcinoma: the Emulsion and CheckMate 214 trials
Current landscape and future direction in systemic therapy for renal cell carcinoma (RCC)